The marked inhibitory effect of tanimilast at low sub-nanomolar concentrations on TNF-α production from COPD AM and lung tissue might, therefore, have important further downstream anti-inflammatory effects on a range of cytokines and chemokines given the role of TNF-α in amplifying the innate immune response. This evidence concerns the gene TNF and chronic obstructive pulmonary disease.